Sanara MedTech Inc.

Good day, ladies and gentlemen, and welcome to the Cenera MedTech, Inc. fourth quarter and full year 2021 results and business update. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, Callan Nichols. Sir, the floor is yours.

Thank you, and good morning, everyone. I'd like to welcome you to Cenera MedTech's earnings conference call for the quarter and full year ended December 31st, 2021. We issued our earnings yesterday afternoon, and I would like to also highlight that we will post today's deck on our investor relations page. The supplemental deck, as well as a copy of the earnings release, the form 10-K, and a transcript of this call will be available on this page. We will reference this information in our remarks today. We expect today's prepared comments from Ron Nixon, Executive Chairman, Zach Fleming, Chief Executive Officer, and Mike McNeil, Chief Financial Officer, to last approximately 15 minutes to allow time for Q&A. Certain statements in this conference call and our press release and in our supplemental deck include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For more information about the risk and uncertainties involved in forward-looking statements, and factors that could cause actual results to vary from those projected or implied by forward-looking statements, please see our most recent annual report on Form 10-K. Now I'd like to turn the call over to Ron Nixon.

Ron Nixon Thank you, Callan, and good morning, everyone. Sonera generated $7 million in revenue and had a net loss of $3.6 million in the fourth quarter of 2021. For the full year, revenues were $24.1 million, representing a 55% increase from the prior year. Our net loss in 2021 was $8 million. Despite impacts from COVID-19 surges throughout the year, our surgical team was able to generate record sales in both the fourth quarter and the full year. Our net loss was largely driven by an increase in SG&A, higher R&D costs, and the recognition of losses on equity method accounting for our investment in precision healing. Throughout the year, the surgical leadership team continued to focus on adding high-quality, experienced regional and territorial sales managers to our sales force, gaining additional hospital approvals, driving product adoption, and introducing new products. Zach will cover more of this in his remarks. In the fourth quarter, we continued to work on our rollout of our EMR wound derm. We also completed the first virtual consult as part of our pilot in the home health industry segment. and continued advancing the development of the wound arm platform. Also in the fourth quarter, we made additions to the board and changes in the leadership team to strengthen our teams. In December, Mike Carmina retired and stepped down from his position as vice chairman of the board and principal executive officer. I'd like to take this opportunity to thank Mike for his years of service at the company and for helping to set the foundation for where we are today. The board made the decision to promote Zach Fleming to Chief Executive Officer in recognition of his leadership skills, strategic vision, and industry expertise. In December, Roz Mack and Eric Hansberger were appointed to our board. Both are value-added board members, and I'm confident that their expertise and experience will add differing perspectives as we continue to execute our strategy. I'd like to turn it over to Zach Fleming to discuss our results in more detail.